Scholar Rock (Nasdaq: SRRK) has unveiled encouraging Phase II data for its experimental therapy apitegromab, showing the drug can reduce the amount of lean mass lost during weight reduction with Eli Lilly’s (NYSE: LLY) weight-loss drug Zepbound (tirzepatide).
In the EMBRAZE trial, patients who received apitegromab in combination with Zepbound experienced more fat loss and retained significantly more muscle than those given Zepbound with placebo. Over the 24-week treatment period, apitegromab preserved 4.2 pounds of lean mass — a 55% improvement over placebo — while both groups lost similar overall body weight.
No serious adverse events or discontinuations tied to apitegromab were reported, and the company described its safety profile as consistent with previous findings.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze